EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Allogeneic haemopoietic cell transplant services in Australia and New Zealand in the first year of the COVID‐19 pandemic: a report from Australia and New Zealand transplant and cellular therapies

Jad Othman iD, Donna Aarons, Ashish Bajel, Jason Butler, Richard Doocey, Tracey O'Brien, Duncan Purtill, Lisa Smith, Leonie Wilcox, Nada Hamad iD

Internal Medicine Journal · 2023-03 · 53 (3) · 323-329

DOI: 10.1111/imj.15886 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 16.09.2022. Verfasst von Jad Othman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The COVID‐19 pandemic has caused major disruption to health systems, with allogeneic haemopoietic cell transplant (alloHCT) services a particularly vulnerable area. Ongoing provision of alloHCT has required dynamic responses at national and local levels. In Australia and New Zealand (ANZ), a high reliance on unrelated donors from overseas registries has posed an additional challenge.

Aims

To describe the impact of COVID‐19 on alloHCT services in ANZ in the first year of the pandemic.

Methods

Data from the national alloHCT patient and unrelated donor registries were extracted for a 2‐year time frame. Comparisons were made between a pre‐pandemic period of 1 March 2019 to 29 February 2020 and the corresponding dates during the pandemic, 1 March 2020 to 28 February 2021.

Results

There was a 13% decrease in the number of allogeneic transplants, a reversal of steady increases in previous years, with the largest decrease in unrelated donor transplants. Local donors supplied a greater proportion of unrelated stem cell products. With a switch to universal cryopreservation, the time from request of a product to infusion increased by a median of 25.5 days for overseas products and 14 days for local products. There was a significant increase in the number of products collected but not used.

Conclusions

A strong public health response and coordinated transplant community activities allowed for safe provision of alloHCT in ANZ; however, our data suggest that the timely delivery of allogeneic transplants was affected by the COVID‐19 pandemic. Continued dedicated efforts are required to minimise further impacts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationCOVID-19HumansPandemicsNew ZealandRetrospective StudiesAustralia

Stichwörter der Autor:innen

COVID-19allogeneic transplantationhaemopoieticregistrystem cell transplantationtransplant donor

Autor:innen und Institutionen

  • Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Australasian Bone Marrow Transplant Recipient Registry, St Vincent's Hospital, Sydney, New South Wales, Australia.
  • Department of Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Department of Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
  • Department of Haematology, Auckland City Hospital, Auckland, New Zealand.
  • Blood & Marrow Transplant Program, Kids Cancer Centre, Sydney Children's Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: Jad Othman, Nada Hamad

Zitieren

APA

Othman, J., Aarons, D., Bajel, A., Butler, J., Doocey, R., O'Brien, T., Purtill, D., Smith, L., Wilcox, L., & Hamad, N. (2023). Allogeneic haemopoietic cell transplant services in Australia and New Zealand in the first year of the COVID‐19 pandemic: a report from Australia and New Zealand transplant and cellular therapies. Internal Medicine Journal, 53(3), 323-329. https://doi.org/10.1111/imj.15886

Vancouver

Othman J, Aarons D, Bajel A, Butler J, Doocey R, O'Brien T, et al. Allogeneic haemopoietic cell transplant services in Australia and New Zealand in the first year of the COVID‐19 pandemic: a report from Australia and New Zealand transplant and cellular therapies. Internal Medicine Journal. 2023;53(3):323-329. doi:10.1111/imj.15886

BibTeX
@article{Othman2023,
  author = {Othman, Jad and Aarons, Donna and Bajel, Ashish and Butler, Jason and Doocey, Richard and O'Brien, Tracey and Purtill, Duncan and Smith, Lisa and Wilcox, Leonie and Hamad, Nada},
  title = {Allogeneic haemopoietic cell transplant services in Australia and New Zealand in the first year of the COVID‐19 pandemic: a report from Australia and New Zealand transplant and cellular therapies},
  journal = {Internal Medicine Journal},
  year = {2023},
  volume = {53},
  number = {3},
  pages = {323--329},
  doi = {10.1111/imj.15886}
}
Kostenlos starten →